KR900016174A - 과혈당증 치료제로서 유용한 나프탈레닐알킬-3h-1,2,3,5-옥사티아디아졸 2-옥사이드 - Google Patents
과혈당증 치료제로서 유용한 나프탈레닐알킬-3h-1,2,3,5-옥사티아디아졸 2-옥사이드 Download PDFInfo
- Publication number
- KR900016174A KR900016174A KR1019900005539A KR900005539A KR900016174A KR 900016174 A KR900016174 A KR 900016174A KR 1019900005539 A KR1019900005539 A KR 1019900005539A KR 900005539 A KR900005539 A KR 900005539A KR 900016174 A KR900016174 A KR 900016174A
- Authority
- KR
- South Korea
- Prior art keywords
- methyl
- oxathiadiazole
- oxide
- naphthalenyl
- compound
- Prior art date
Links
- 201000001421 hyperglycemia Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 30
- 150000003839 salts Chemical class 0.000 claims 26
- -1 4-[(1-bromo-3-methyl-2-naphthalenyl) ethyl] -3H-1,2,3,5-oxathiadiazole 2-oxide Chemical compound 0.000 claims 4
- 125000004432 carbon atom Chemical group C* 0.000 claims 4
- 229910052736 halogen Inorganic materials 0.000 claims 4
- 150000002367 halogens Chemical class 0.000 claims 4
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 125000000217 alkyl group Chemical group 0.000 claims 3
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims 3
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims 3
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 239000001257 hydrogen Substances 0.000 claims 3
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 3
- 150000002825 nitriles Chemical class 0.000 claims 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 3
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims 3
- 229920002554 vinyl polymer Polymers 0.000 claims 3
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 claims 2
- IIIDRTFTHXHVBI-UHFFFAOYSA-N 4-[(1-bromonaphthalen-2-yl)methyl]-5h-1,2,3,5-oxathiadiazole 2-oxide Chemical compound C1=CC2=CC=CC=C2C(Br)=C1CC1=NOS(=O)N1 IIIDRTFTHXHVBI-UHFFFAOYSA-N 0.000 claims 1
- NFYYUNIYQZYQMQ-UHFFFAOYSA-N 4-[(1-chloronaphthalen-2-yl)methyl]-5h-1,2,3,5-oxathiadiazole 2-oxide Chemical compound C1=CC2=CC=CC=C2C(Cl)=C1CC1=NOS(=O)N1 NFYYUNIYQZYQMQ-UHFFFAOYSA-N 0.000 claims 1
- FWUKKBWRHPNAAM-UHFFFAOYSA-N 4-[(1-fluoronaphthalen-2-yl)methyl]-5h-1,2,3,5-oxathiadiazole 2-oxide Chemical compound C1=CC2=CC=CC=C2C(F)=C1CC1=NOS(=O)N1 FWUKKBWRHPNAAM-UHFFFAOYSA-N 0.000 claims 1
- YSFAKBXKUIMVBG-UHFFFAOYSA-N 4-[(1-methoxynaphthalen-2-yl)methyl]-5h-1,2,3,5-oxathiadiazole 2-oxide Chemical compound C1=CC2=CC=CC=C2C(OC)=C1CC1=NOS(=O)N1 YSFAKBXKUIMVBG-UHFFFAOYSA-N 0.000 claims 1
- BPIZTFHPFHJWQE-UHFFFAOYSA-N 4-[(1-methylnaphthalen-2-yl)methyl]-5h-1,2,3,5-oxathiadiazole 2-oxide Chemical compound C1=CC2=CC=CC=C2C(C)=C1CC1=NOS(=O)N1 BPIZTFHPFHJWQE-UHFFFAOYSA-N 0.000 claims 1
- VLGGHKKXIATZJB-UHFFFAOYSA-N 4-[(1-nitronaphthalen-2-yl)methyl]-5h-1,2,3,5-oxathiadiazole 2-oxide Chemical compound C1=CC2=CC=CC=C2C([N+](=O)[O-])=C1CC1=NOS(=O)N1 VLGGHKKXIATZJB-UHFFFAOYSA-N 0.000 claims 1
- PEDHJCWBEYKPPW-UHFFFAOYSA-N 4-[(3-bromo-4-methoxynaphthalen-1-yl)methyl]-5h-1,2,3,5-oxathiadiazole 2-oxide Chemical compound C12=CC=CC=C2C(OC)=C(Br)C=C1CC1=NOS(=O)N1 PEDHJCWBEYKPPW-UHFFFAOYSA-N 0.000 claims 1
- MMPQIPDNOSQEJW-UHFFFAOYSA-N 4-[(3-chloronaphthalen-2-yl)methyl]-5h-1,2,3,5-oxathiadiazole 2-oxide Chemical compound ClC1=CC2=CC=CC=C2C=C1CC1=NOS(=O)N1 MMPQIPDNOSQEJW-UHFFFAOYSA-N 0.000 claims 1
- DQEGBYIXHLYGMW-UHFFFAOYSA-N 4-[(3-methoxynaphthalen-2-yl)methyl]-5h-1,2,3,5-oxathiadiazole 2-oxide Chemical compound COC1=CC2=CC=CC=C2C=C1CC1=NOS(=O)N1 DQEGBYIXHLYGMW-UHFFFAOYSA-N 0.000 claims 1
- KGVJYCNHKKGCRR-UHFFFAOYSA-N 4-[(3-methylnaphthalen-2-yl)methyl]-5h-1,2,3,5-oxathiadiazole 2-oxide Chemical compound CC1=CC2=CC=CC=C2C=C1CC1=NOS(=O)N1 KGVJYCNHKKGCRR-UHFFFAOYSA-N 0.000 claims 1
- ZHRKNKOPKDYXFF-UHFFFAOYSA-N 4-[(4-chloro-1-methoxynaphthalen-2-yl)methyl]-5h-1,2,3,5-oxathiadiazole 2-oxide Chemical compound C1=C(Cl)C2=CC=CC=C2C(OC)=C1CC1=NOS(=O)N1 ZHRKNKOPKDYXFF-UHFFFAOYSA-N 0.000 claims 1
- YKPWJBAXANCTHR-UHFFFAOYSA-N 4-[(5-bromonaphthalen-2-yl)methyl]-5h-1,2,3,5-oxathiadiazole 2-oxide Chemical compound C=1C=C2C(Br)=CC=CC2=CC=1CC1=NOS(=O)N1 YKPWJBAXANCTHR-UHFFFAOYSA-N 0.000 claims 1
- AFSHNJLKCYAWRX-UHFFFAOYSA-N 4-[(5-chloronaphthalen-2-yl)methyl]-5h-1,2,3,5-oxathiadiazole 2-oxide Chemical compound C=1C=C2C(Cl)=CC=CC2=CC=1CC1=NS(=O)ON1 AFSHNJLKCYAWRX-UHFFFAOYSA-N 0.000 claims 1
- HIQRGNIWZRATAC-UHFFFAOYSA-N 4-[(5-ethynylnaphthalen-2-yl)methyl]-5h-1,2,3,5-oxathiadiazole 2-oxide Chemical compound O1S(=O)NC(CC=2C=C3C=CC=C(C3=CC=2)C#C)=N1 HIQRGNIWZRATAC-UHFFFAOYSA-N 0.000 claims 1
- XQBVUFSOCILYHF-UHFFFAOYSA-N 4-[(5-methylnaphthalen-2-yl)methyl]-5h-1,2,3,5-oxathiadiazole 2-oxide Chemical compound C=1C=C2C(C)=CC=CC2=CC=1CC1=NOS(=O)N1 XQBVUFSOCILYHF-UHFFFAOYSA-N 0.000 claims 1
- PYRBZYPOQXTXDW-UHFFFAOYSA-N 4-[(8-bromonaphthalen-1-yl)methyl]-5h-1,2,3,5-oxathiadiazole 2-oxide Chemical compound C=12C(Br)=CC=CC2=CC=CC=1CC1=NOS(=O)N1 PYRBZYPOQXTXDW-UHFFFAOYSA-N 0.000 claims 1
- VTQXRSXPYDITJE-UHFFFAOYSA-N 4-[(8-bromonaphthalen-2-yl)methyl]-5h-1,2,3,5-oxathiadiazole 2-oxide Chemical compound C1=C2C(Br)=CC=CC2=CC=C1CC1=NOS(=O)N1 VTQXRSXPYDITJE-UHFFFAOYSA-N 0.000 claims 1
- ISZUYVHHYQEAJH-UHFFFAOYSA-N 4-[2-(5-bromonaphthalen-2-yl)ethyl]-5h-1,2,3,5-oxathiadiazole 2-oxide Chemical compound C=1C=C2C(Br)=CC=CC2=CC=1CCC1=NOS(=O)N1 ISZUYVHHYQEAJH-UHFFFAOYSA-N 0.000 claims 1
- WYQFXPXDVAEHLQ-UHFFFAOYSA-N 4-[[3-(trifluoromethyl)naphthalen-2-yl]methyl]-5h-1,2,3,5-oxathiadiazole 2-oxide Chemical compound FC(F)(F)C1=CC2=CC=CC=C2C=C1CC1=NOS(=O)N1 WYQFXPXDVAEHLQ-UHFFFAOYSA-N 0.000 claims 1
- FVOQTFJKCZGTLV-UHFFFAOYSA-N 4-[[5-(trifluoromethyl)naphthalen-2-yl]methyl]-5h-1,2,3,5-oxathiadiazole 2-oxide Chemical compound C=1C=C2C(C(F)(F)F)=CC=CC2=CC=1CC1=NOS(=O)N1 FVOQTFJKCZGTLV-UHFFFAOYSA-N 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D291/00—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms
- C07D291/02—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms not condensed with other rings
- C07D291/04—Five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Abstract
내용 없음.
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (28)
- 일반식(I)의 화합물 또는 이의 약제학적으로 허용되는 염.상기식에서, R1및 R2는 독립적으로 수소, 탄소수 1 내지 6의 저급알킬, 탄소수 1 내지 6의 알콕시, 할로겐, 에티닐, 니트릴, 메틸티오, 트리플루오로메틸, 비닐, 니트로, 또는 할로겐-치환된 벤질옥시이고, n은 0 내지 4이다.
- 제1항에 있어서, 일반식(II)의 화합물 또는 이의 약제학적으로 허용되는 염.상기식에서, R1및 R2는 독립적으로 수소, 탄소수 1 내지 6의 저급알킬, 탄소수 1 내지 6의 알콕시, 할로겐, 에티닐, 니트릴, 트리플루오로메틸, 비닐 또는 니트로이고, n은 1 또는 2이다.
- 제2항에 있어서, 4-[(5-브로모-2-나프탈레닐)메틸]-3H-1,2,3,5-옥사티아디아졸 2-옥사이드인 화합물 또는 이의 약제학적으로 허용되는 염.
- 제2항에 있어서, 4-[(8-브로모-2-나프탈레닐)메틸]-3H-1,2,3,5-옥사티아디아졸 2-옥사이드인 화합물 또는 이의 약제학적으로 허용되는 염.
- 제2항에 있어서, 4-[(1-브로모-2-나프탈레닐)메틸]-3H-1,2,3,5-옥사티아디아졸 2-옥사이드인 화합물 또는 이의 약제학적으로 허용되는 염.
- 제2항에 있어서, 4-[(3-메틸-2-나프탈레닐)메틸]-3H-1,2,3,5-옥사티아디아졸 2-옥사이드인 화합물 또는 이의 약제학적으로 허용되는 염.
- 제2항에 있어서, 4-[2-(5-브로모-2-나프탈레닐)에틸]-3H-1,2,3,5-옥사티아디아졸 2-옥사이드인 화합물 또는 이의 약제학적으로 허용되는 염.
- 제2항에 있어서, 4-[(5-클로로-2-나프탈레닐)메틸]-3H-1,2,3,5-옥사티아디아졸 2-옥사이드인 화합물 또는 이의 약제학적으로 허용되는 염.
- 제2항에 있어서, 4-[(1-메틸-2-나프탈레닐)메틸]-3H-1,2,3,5-옥사티아디아졸 2-옥사이드인 화합물 또는 이의 약제학적으로 허용되는 염.
- 제2항에 있어서, 4-[(1-클로로-2-나프탈레닐)메틸]-3H-1,2,3,5-옥사티아디아졸 2-옥사이드인 화합물 또는 이의 약제학적으로 허용되는 염.
- 제2항에 있어서, 4-[(3-메톡시-2-나프탈레닐)메틸]-3H-1,2,3,5-옥사티아디아졸 2-옥사이드인 화합물 또는 이의 약제학적으로 허용되는 염.
- 제2항에 있어서, 4-[(3-클로로-2-나프탈레닐)메틸]-3H-1,2,3,5-옥사티아디아졸 2-옥사이드인 화합물 또는 이의 약제학적으로 허용되는 염.
- 제2항에 있어서, 4-[(4-클로로-1-메톡시-2-나프탈레닐)메틸]-3H-1,2,3,5-옥사티아디아졸 2-옥사이드인 화합물 또는 이의 약제학적으로 허용되는 염.
- 제2항에 있어서, 4-[(1-메톡시-2-나프탈레닐)메틸]-3H-1,2,3,5-옥사티아디아졸 2-옥사이드인 화합물 또는 이의 약제학적으로 허용되는 염.
- 제2항에 있어서, 4-[(1-브로모-3-메틸-2-나프탈레닐)에틸]-3H-1,2,3,5-옥사티아디아졸 2-옥사이드인 화합물 또는 이의 약제학적으로 허용되는 염.
- 제2항에 있어서, 4-[(1-플루오로-2-나프탈레닐)메틸]-3H-1,2,3,5-옥사티아디아졸 2-옥사이드인 화합물 또는 이의 약제학적으로 허용되는 염.
- 제2항에 있어서, 4-[[5-(트리플루오로메틸)2-나프탈레닐]메틸]-3H-1,2,3,5-옥사티아디아졸 2-옥사이드인 화합물 또는 이의 약제학적으로 허용되는 염.
- 제2항에 있어서, 4-[(5-메틸-2-나프탈레닐)메틸]-3H-1,2,3,5-옥사티아디아졸 2-옥사이드인 화합물 또는 이의 약제학적으로 허용되는 염.
- 제2항에 있어서, 4-[[3-(트리플루오로메틸)2-나프탈레닐]메틸]-3H-1,2,3,5-옥사티아디아졸 2-옥사이드인 화합물 또는 이의 약제학적으로 허용되는 염.
- 제2항에 있어서, 4-[(5-에티닐-2-나프탈레닐)메틸]-3H-1,2,3,5-옥사티아디아졸 2-옥사이드인 화합물 또는 이의 약제학적으로 허용되는 염.
- 제2항에 있어서, [4-[(8-클로로-2-나프탈레닐)메틸]-3H-1,2,3,5-옥사티아디아졸 2-옥사이드인 화합물 또는 이의 약제학적으로 허용되는 염.
- 제2항에 있어서, 4-[(4-브로모-1-메톡시-2-나프탈레닐)메틸]-3H-1,2,3,5-옥사티아디아졸 2-옥사이드인 화합물 또는 이의 약제학적으로 허용되는 염.
- 제2항에 있어서, 4-[(1-니트로-2-나프탈레닐)메틸]-3H-1,2,3,5-옥사티아디아졸 2-옥사이드인 화합물 또는 이의 약제학적으로 허용되는 염.
- 제2항에 있어서, 4-[(8-브로모-1-나프탈레닐)메틸]-3H-1,2,3,5-옥사티아디아졸 2-옥사이드인 화합물 또는 이의 약제학적으로 허용되는 염.
- 제2항에 있어서, 4-[(3-브로모-4-메톡시-1-나프탈레닐)메틸]-3H-1,2,3,5-옥사티아디아졸 2-옥사이드인 화합물 또는 이의 약제학적으로 허용되는 염.
- (a) 일반식(III)의 니트릴 화합물을 H2NOH와 반응시켜 일반식(II)의 이미드아미드를 제조한 후, (b) 생성된 이미드아미드를 SOCl2와 반응시킴을 특징으로 하여, 일반식(I)의 화합물 또는 이의 약제학적으로 허용하는 염을 제조하는 방법.상기식에서, R1또는 R2는 독립적으로 수소, 탄소수 1 내지 6의 저급 알킬, 탄소수 1 내지 6의 알콕시, 할로겐, 아세틸렌, 니트릴, 메틸티오, 트리플루오로메틸, 비닐, 니트로, 또는 할로겐 치환된 벤질옥시이고, n은 0 내지 4이다.
- 유효량의 제1항에 따른 화합물을 투여시켜 인간의 비-인슐린 의존성 당뇨병을 치료하는 방법.
- 제1항의 화합물 및 약제학적으로 허용되는 담체를 함유하는 약제학적 조성물.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/341,340 US4897405A (en) | 1989-04-21 | 1989-04-21 | Novel naphthalenylalkyl-3H-1,2,3,5-oxathiadiazole 2-oxides useful as antihyperglycemic agents |
US341340 | 1989-04-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
KR900016174A true KR900016174A (ko) | 1990-11-12 |
Family
ID=23337136
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019900005539A KR900016174A (ko) | 1989-04-21 | 1990-04-20 | 과혈당증 치료제로서 유용한 나프탈레닐알킬-3h-1,2,3,5-옥사티아디아졸 2-옥사이드 |
Country Status (12)
Country | Link |
---|---|
US (1) | US4897405A (ko) |
JP (1) | JPH02292272A (ko) |
KR (1) | KR900016174A (ko) |
CN (1) | CN1046528A (ko) |
CA (1) | CA2015032A1 (ko) |
DD (1) | DD298925A5 (ko) |
FI (1) | FI901956A0 (ko) |
HU (1) | HUT54360A (ko) |
IL (1) | IL94068A0 (ko) |
NO (1) | NO901728L (ko) |
PT (1) | PT93812A (ko) |
ZA (1) | ZA903018B (ko) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4142956C2 (de) * | 1991-12-24 | 1996-08-14 | Du Pont Deutschland | Bleichbares Lichthofschutzsystem für photographische Aufzeichnungsmaterialien |
CN1103590C (zh) * | 1993-09-15 | 2003-03-26 | 三共株式会社 | 使用噻唑烷二酮防止或延缓非胰岛素依赖性糖尿病(niddm)的发作 |
US6046222A (en) * | 1993-09-15 | 2000-04-04 | Warner-Lambert Company | Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome, gestational diabetes and disease states at risk for progressing to noninsulin-dependent diabetes mellitus |
US5874454A (en) * | 1993-09-15 | 1999-02-23 | Warner-Lambert Company | Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome, gestational diabetes and disease states at risk for progressing to noninsulin-dependent diabetes mellitus |
US5457109A (en) * | 1993-09-15 | 1995-10-10 | Warner-Lambert Company | Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of disease states at risk for progressing to noninsulin-dependent diabetes mellitus |
US5399588A (en) * | 1993-12-14 | 1995-03-21 | American Home Products Corporation | Naphthalenylmethyl cycloalkenone acetic acids and analogs thereof useful as aldose reductase inhibitors |
US5444086A (en) * | 1994-03-31 | 1995-08-22 | American Home Products Corporation | Naphthalenylmethyl thiophenones as antihyperglycemic agents |
US5597826A (en) | 1994-09-14 | 1997-01-28 | Pfizer Inc. | Compositions containing sertraline and a 5-HT1D receptor agonist or antagonist |
US5708012A (en) * | 1995-04-28 | 1998-01-13 | Sankyo Company, Limited | Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of insulin resistant subjects with normal glucose tolerance in order to prevent or delay the onset of noninsulin-dependent mellitus |
CA2180296C (en) * | 1995-07-03 | 2007-01-09 | Yoshio Tsujita | Treatment of arteriosclerosis and xanthoma |
NZ313896A (en) * | 1995-08-28 | 2000-08-25 | American Home Prod | 4-formyl-2-(naphthalenylmethyl)phenoxyacetic acids or salts and antihyperglycemic agents for the treatment of diabetes mellitus |
AU7604596A (en) * | 1995-11-17 | 1997-06-11 | Warner-Lambert Company | A method of treating myotonic dystrophy |
CA2257284C (en) * | 1996-05-31 | 2005-10-04 | Sankyo Company Limited | Remedy for autoimmune diseases |
WO1998039967A1 (en) * | 1997-03-12 | 1998-09-17 | The General Hospital Corporation | A method for treating or preventing alzheimer's disease |
HUP9902721A2 (hu) | 1997-11-25 | 1999-12-28 | The Procter & Gamble Co. | Tömény textillágyító készítmény és ehhez alkalmazható magas telítetlenségű textillágyító vegyület |
US20040058873A1 (en) * | 1998-03-12 | 2004-03-25 | Esmond Robert W. | Method for treating or preventing Alzheimer's disease |
WO2000030628A2 (en) * | 1998-11-20 | 2000-06-02 | Genentech, Inc. | Method of inhibiting angiogenesis |
US6191154B1 (en) | 1998-11-27 | 2001-02-20 | Case Western Reserve University | Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases |
WO2001077076A1 (fr) * | 1999-06-02 | 2001-10-18 | Torii Pharmaceutical Co., Ltd. | Nouveaux derives de naphtalene |
JP2001072592A (ja) | 1999-07-01 | 2001-03-21 | Kyowa Hakko Kogyo Co Ltd | テロメラーゼ阻害剤 |
US6680387B2 (en) * | 2000-04-24 | 2004-01-20 | Aryx Therapeutics | Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis |
US6958355B2 (en) * | 2000-04-24 | 2005-10-25 | Aryx Therapeutics, Inc. | Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis |
AU2001294673A1 (en) * | 2000-09-21 | 2002-04-02 | Aryx Therapeutics | Isoxazolidine compounds useful in the treatment of diabetes, hyperlipidemia, andatherosclerosis |
US6452014B1 (en) | 2000-12-22 | 2002-09-17 | Geron Corporation | Telomerase inhibitors and methods of their use |
US20060047000A1 (en) * | 2001-04-24 | 2006-03-02 | Aryx Therapeutics, Inc. | Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis |
US20070269486A1 (en) * | 2005-03-14 | 2007-11-22 | Conor Medsystems, Llc. | Methods and Devices for Reducing Tissue Damage After Ischemic Injury |
PL2068909T3 (pl) | 2007-03-30 | 2012-09-28 | Ambrx Inc | Modyfikowane polipeptydy fgf-21 i ich zastosowanie |
WO2009129317A1 (en) * | 2008-04-15 | 2009-10-22 | Burnham Institute For Medical Research | An inhibitor of anti-apoptotic proteins |
EP2683705B1 (de) | 2011-03-08 | 2015-04-22 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
ES2668310T3 (es) | 2012-11-05 | 2018-05-17 | Commissariat à l'énergie atomique et aux énergies alternatives | Combinación de un agente anticanceroso tal como un inhibidor de la tirosina cinasa y un antagonista STAT5, preferiblemente una tiazolidindiona, para eliminar las células madre de cáncer hematológico in vivo y para prevenir la recidiva de cáncer hematológico |
DK3412302T3 (da) | 2014-10-24 | 2021-07-12 | Bristol Myers Squibb Co | Modificerede fgf-21-polypeptider og anvendelser deraf |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4148801A (en) * | 1978-07-03 | 1979-04-10 | American Home Products Corporation | 3-[(Chlorophenylsulfonyl)methyl]-1,2,4-oxadiazole-5-carboxylic acid derivatives |
JPS5925466U (ja) * | 1982-08-10 | 1984-02-17 | 安部 義雄 | 標準貫入試験装置 |
JPS59107636U (ja) * | 1982-12-29 | 1984-07-20 | ナショナル住宅産業株式会社 | 地耐力測定装置 |
JPS6095021A (ja) * | 1983-10-31 | 1985-05-28 | Natl House Ind Co Ltd | 地耐力測定装置 |
JPH0516270Y2 (ko) * | 1986-03-19 | 1993-04-28 | ||
JPH0372937U (ko) * | 1989-11-16 | 1991-07-23 |
-
1989
- 1989-04-21 US US07/341,340 patent/US4897405A/en not_active Expired - Lifetime
-
1990
- 1990-04-12 IL IL94068A patent/IL94068A0/xx unknown
- 1990-04-19 PT PT93812A patent/PT93812A/pt not_active Application Discontinuation
- 1990-04-19 FI FI901956A patent/FI901956A0/fi not_active Application Discontinuation
- 1990-04-19 NO NO90901728A patent/NO901728L/no unknown
- 1990-04-20 JP JP2106328A patent/JPH02292272A/ja active Pending
- 1990-04-20 CA CA002015032A patent/CA2015032A1/en not_active Abandoned
- 1990-04-20 KR KR1019900005539A patent/KR900016174A/ko not_active Application Discontinuation
- 1990-04-20 ZA ZA903018A patent/ZA903018B/xx unknown
- 1990-04-20 HU HU902496A patent/HUT54360A/hu unknown
- 1990-04-20 DD DD90339956A patent/DD298925A5/de not_active IP Right Cessation
- 1990-04-20 CN CN90102330A patent/CN1046528A/zh active Pending
Also Published As
Publication number | Publication date |
---|---|
ZA903018B (en) | 1991-12-24 |
DD298925A5 (de) | 1992-03-19 |
HUT54360A (en) | 1991-02-28 |
CN1046528A (zh) | 1990-10-31 |
NO901728D0 (no) | 1990-04-19 |
CA2015032A1 (en) | 1990-10-21 |
NO901728L (no) | 1990-10-22 |
JPH02292272A (ja) | 1990-12-03 |
HU902496D0 (en) | 1990-08-28 |
US4897405A (en) | 1990-01-30 |
IL94068A0 (en) | 1991-01-31 |
FI901956A0 (fi) | 1990-04-19 |
PT93812A (pt) | 1990-11-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR900016174A (ko) | 과혈당증 치료제로서 유용한 나프탈레닐알킬-3h-1,2,3,5-옥사티아디아졸 2-옥사이드 | |
RU92004433A (ru) | Ароматические аминоспиртовые производные, способ их получения и фармацевтическая композиция | |
KR830001926A (ko) | 신규한 퀴나조린 유도체 및 그의 부가염의 제조방법 | |
KR940019699A (ko) | 옥사졸리딘디온 유도체, 그의 제조방법 및 용도 | |
RU96123713A (ru) | Тиадиазолы и их применение в качестве противопикорнавирусного средства | |
ATE94879T1 (de) | Makrolid-verbindungen. | |
KR830007631A (ko) | 2-피리딘카복스아미드 유도체 및 이들의 제조방법 | |
IT1206130B (it) | Composti per abbassare i livelli dei lipidi. | |
KR910016734A (ko) | 광학활성 알킬렌디옥시벤젠 유도체 및 치료에의 용도 | |
KR900014397A (ko) | 티에노-트리아졸로-디아제핀 술포닐 유도체, 그의 제조 방법 및 그를 함유하는 치료 조성물 | |
KR870004006A (ko) | 5-아릴-2,4-디알킬-3h-1,2,4-트리아졸-3-티온 및 이의 제조 방법 | |
KR900014325A (ko) | 아졸-1-알칸아미드, 그의 제조방법 및 그를 함유하는 심장부정맥 치료를 위한 조성물 | |
KR900018128A (ko) | 카르복스아미드 유도체 | |
KR940005621A (ko) | 벤조[b]티오펜-3-일-피페라진. 이의 제조방법 및 약제로서 이의 용도 | |
KR900016173A (ko) | 항과 혈당증제로서 유용한 나프탈레닐-3h-1,2,3,5-옥사티아디아졸 2-옥사이드 | |
KR890002079A (ko) | 1-[2-(페닐메틸)페닐]피페라진 및 그의 제조방법 | |
KR900001665A (ko) | 사이클로알킬티아졸 유도체 | |
KR880013929A (ko) | 신규 5-메톡시 알킬 암노늄 테트라히드로푸란 및 테트라히드로티오펜 | |
KR890012961A (ko) | N-(저급알킬)-2-(3'-우레이도벤질)피롤리딘 | |
KR880001630A (ko) | 5-플루오로우라실 유도체 및 그의 용도 | |
KR920019739A (ko) | 약학적 화합물 | |
KR870001153A (ko) | 디페녹시에틸아민 유도체가 함유된 약제조성물 및 그의 생산방법 | |
DE3583791D1 (de) | Spiro-hydantoine fuer die behandlung von diabetischen komplikationen. | |
KR900014297A (ko) | 치환된 비페닐 | |
ATE144900T1 (de) | Verwendung von xanthinderivaten gegen magengeschwüre |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |